EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR‐ABL1 transcript decline velocity in chronic myeloid leukemia: A 16‐year real‐world study

Moaath K Mustafa Ali iD, Emily C Zabor, Kamilla Abdurakhmanov iD, Hadil Zureigat, Ahmed N Mohamed iD, Muaz Alsabbagh Alchirazi, Aastha Dhakal, Ali Mushtaq, Naveen Rehman, Ameed Bawwab, Bryan Berube, Lana Khatib und 10 weitere

Cancer · 2026

DOI: 10.1002/cncr.70524 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Moaath K Mustafa Ali und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Fusion Proteins, bcr-abl, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

No large, randomized trials have compared three or more tyrosine kinase inhibitors (TKIs) in a single chronic myeloid leukemia (CML) cohort. Most studies are two‐arm comparisons versus imatinib, or rely on indirect methods.

Methods

A retrospective cohort study was conducted of 349 patients with chronic‐ and accelerated‐phase CML treated between 2007 and 2023 at Cleveland Clinic centers in Northeast Ohio. Overall survival (OS), event‐free survival (EFS), 12‐month therapeutic milestone achievement, and BCR‐ABL1 transcript decline velocity across first‐, second‐, and third‐line TKIs were compared. Baseline demographics, comorbidities, cytogenetics, and hematologic parameters were collected. Multivariable regression and time‐dependent Cox models were adjusted for confounders and varying therapy initiation times.

Results

First‐line TKIs included imatinib (53%), dasatinib (30%), nilotinib (15%), and bosutinib (2%). Median age ranged from 52 to 60 years, most patients were White, and high‐risk cytogenetics were rare. Five‐year OS ranged from 78% for dasatinib to 90% for nilotinib, with nilotinib associated with improved OS (hazard ratio [HR], 0.43) and EFS (HR, 0.48) and the fastest BCR‐ABL1 decline (β = −8.3%) versus imatinib. In second‐ ( n = 181) and third‐line therapy ( n = 91), no significant differences in outcomes were observed. Across all lines, time‐dependent modeling showed improved EFS only for nilotinib (HR, 0.61). Unadjusted OS was higher in patients starting treatment in 2007–2010 versus later periods but differences disappeared after adjustment.

Conclusions

Real‐world data indicate that imatinib achieves comparable response rates to newer TKIs, with durable survival. Nilotinib consistently shows faster BCR‐ABL1 decline and improved EFS overall, consistent with prior network meta‐analyses. Lack of improvement in OS over time suggests the need to investigate factors influencing long‐term outcomes in CML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsFusion Proteins, bcr-ablLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansFemaleRetrospective StudiesMiddle AgedMaleImatinib MesylatePyrimidinesDasatinibTreatment OutcomeLongitudinal StudiesNitrilesAniline CompoundsQuinolines

Stichwörter der Autor:innen

BCR‐ABL1 kineticschronic myeloid leukemiaevent‐free survivaloverall survivaltyrosine kinase inhibitors

Substanzen

Protein Kinase InhibitorsFusion Proteins, bcr-ablImatinib MesylatePyrimidinesnilotinibDasatinibBCR-ABL1 fusion protein, humanbosutinibNitrilesAniline Compounds

Autor:innen und Institutionen

  • Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
  • Department of Quantitative Health Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, USA.
  • Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA.

ORCID-Profile: Moaath K Mustafa Ali, Kamilla Abdurakhmanov, Ahmed N Mohamed, Akriti G Jain

Zitieren

APA

Mustafa Ali, M. K., Zabor, E. C., Abdurakhmanov, K., Zureigat, H., Mohamed, A. N., Alchirazi, M. A., Dhakal, A., Mushtaq, A., Rehman, N., Bawwab, A., Berube, B., Khatib, L., Jain, A. G., Molina, J. C., Balderman, S., Singh, A., Gerds, A. T., Sobecks, R., Advani, A. S., …, & Mukherjee, S. (2026). Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR‐ABL1 transcript decline velocity in chronic myeloid leukemia: A 16‐year real‐world study. Cancer. https://doi.org/10.1002/cncr.70524

Vancouver

Mustafa Ali MK, Zabor EC, Abdurakhmanov K, Zureigat H, Mohamed AN, Alchirazi MA, et al. Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR‐ABL1 transcript decline velocity in chronic myeloid leukemia: A 16‐year real‐world study. Cancer. 2026. doi:10.1002/cncr.70524

BibTeX
@article{MustafaAli2026,
  author = {Mustafa Ali, Moaath K and Zabor, Emily C and Abdurakhmanov, Kamilla and Zureigat, Hadil and Mohamed, Ahmed N and Alchirazi, Muaz Alsabbagh and Dhakal, Aastha and Mushtaq, Ali and Rehman, Naveen and Bawwab, Ameed and Berube, Bryan and Khatib, Lana and Jain, Akriti G and Molina, John C and Balderman, Sophia and Singh, Abhay and Gerds, Aaron T and Sobecks, Ronald and Advani, Anjali S and Carraway, Hetty E and Kalaycio, Matt and Mukherjee, Sudipto},
  title = {Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR‐ABL1 transcript decline velocity in chronic myeloid leukemia: A 16‐year real‐world study},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70524}
}
Kostenlos starten →